Siemens Healthineers AG Unsponsored ADR (SMMNY)
OTC PINK OTC PINK Primary 
Siemens Healthineers AG (SMMNY) Analyst/Investor Day Transcript
Siemens Healthineers AG (OTCPK:SMMNY) Analyst/Investor Day November 17, 2025 8:00 AM EST Company Participants Bernhard Montag - President, CEO & Chairman of Management Board Jochen Schmitz - CFO & Member of Management Board Andre Hartung - Head of Diagnostic Imaging Marc Koebernick - Head of Investor Relations Arthur Kaindl - Head of Varian Carsten Bertram - Head of Advanced Therapies Dorin Comaniciu Conference Call Participants Veronika Dubajova - Citigroup Inc., Research Division David Adlington - JPMorgan Chase & Co, Research Division Hassan Al-Wakeel - Barclays Bank PLC, Research Division Graham Doyle - UBS Investment Bank, Research Division Hugo Solvet - BNP Paribas, Research Division Julien Ouaddour - BofA Securities, Research Division Julien Dormois - Jefferies LLC, Research Division Richard Felton - Goldman Sachs Group, Inc., Research Division Oliver Metzger - ODDO BHF Corporate & Markets, Research Division Oliver Reinberg - Kepler Cheuvreux, Research Division Andrew Hemming Presentation Operator Great. So when we set off the plan this day, by the way, thanks to Jefferies for giving us kind of a bit of a room within their huge conference.
Siemens Healthineers: Healthcare Remains Attractive After 2025
Siemens Healthineers remains a Buy, offering 15% annualized upside. Strong 2025 results, margin expansion, and resilient growth in Imaging and Varian segments support the investment case, despite China and tariff headwinds. Risks include ongoing diagnostics transformation, Chinese market uncertainty, and tariff impacts, but these are factored into current valuation and outlook.
Siemens Healthineers AG (SMMNY) Q4 2025 Press Conference Call Transcript
Siemens Healthineers AG (OTCPK:SMMNY) Q4 2025 Press Conference Call November 5, 2025 4:00 AM EST Company Participants Matthias Kraemer Bernhard Montag - President, CEO & Chairman of Management Board Jochen Schmitz - CFO & Member of Management Board Presentation Matthias Kraemer Good morning, ladies and gentlemen. Welcome to our annual press conference for fiscal 2025.
Siemens Healthineers AG (SMMNY) Q4 2025 Earnings Call Transcript
Siemens Healthineers AG (OTCPK:SMMNY) Q4 2025 Earnings Call November 5, 2025 2:00 AM EST Company Participants Marc Koebernick - Head of Investor Relations Bernhard Montag - President, CEO & Chairman of Management Board Jochen Schmitz - CFO & Member of Management Board Conference Call Participants Veronika Dubajova - Citigroup Inc., Research Division Hassan Al-Wakeel - Barclays Bank PLC, Research Division David Adlington - JPMorgan Chase & Co, Research Division Julien Ouaddour - BofA Securities, Research Division Oliver Reinberg - Kepler Cheuvreux, Research Division Falko Friedrichs - Deutsche Bank AG, Research Division Julien Dormois - Jefferies LLC, Research Division Hugo Solvet - BNP Paribas, Research Division Oliver Metzger - ODDO BHF Corporate & Markets, Research Division Samuel England - Joh. Berenberg, Gossler & Co. KG, Research Division Richard Felton - Goldman Sachs Group, Inc., Research Division Presentation Operator Good morning, ladies and gentlemen, and welcome to Siemens Healthineers' Conference Call.
Siemens Healthineers Reports Fall in Profits, Citing Tariffs
Higher comparable revenue stemming from the transformation program of its diagnostics business was offset by a hit from U.S. tariffs.
Siemens Healthineers slightly misses sales expectations in fourth quarter
Siemens Healthineers on Wednesday reported fourth-quarter revenue slightly below analysts' consensus as higher U.S. import tariffs weigh.
Siemens AG Considers Spin-Off Of Siemens Healthineers Stake
Deal OverviewOn October 2, 2025, reports surfaced that Siemens AG (US OTC: SIEGY ADR, $142.89; Market Capitalization: $228.6 billion) is actively evaluating a potential spin-off of a substantial portion of its majority stake in Siemens Healthineers (US OTC: SMMNY ADR, $27.31; Market Capitalization: $61.6 billion), its publicly listed medical technology subsidiary.
Siemens Healthineers AG - Special Call
Siemens Healthineers AG - Special Call Company Participants Presentation Unknown Executive Welcome to our pre-close catch-up for Q4 fiscal year 2025, which was recorded on September 25, 2025. In this podcast, we sum up and repeat relevant topics, which were communicated in public as potentially relevant for the upcoming quarter.
Siemens Healthineers meets Q3 sales expectations, raises guidance
German medical technology company Siemens Healthineers on Wednesday reported third-quarter revenue slightly above analysts' consensus, citing strong growth in its China business after declines last year.
Siemens Healthineers: More Upside Is Possible
Siemens Healthineers AG remains a Buy with a €53/share price target, offering 15%+ annualized upside and strong fundamentals despite recent volatility. Recent results show robust revenue and margin growth, especially in Imaging and Varian, with positive trends in Asia and North America driving performance. Key risks are valuation sensitivity above €53/share and ongoing diagnostics transformation, but operational risks remain low and credit quality is high.
Healthineers: Reviewing Q2 And Updating My Targets (Rating Upgrade)
Siemens Healthineers reported strong Q2 '25 results, with 7% top-line growth and confirmed full-year outlook, despite challenges in China and tariffs. The company excels in imaging, holding a 37% market share, and its Varian acquisition boosts its radiotherapy segment, though diagnostics remain a challenge. Valuation is attractive at sub-€48/share, with a price target of €53/share, offering a potential upside of 14-25% annually.
Siemens Healthineers Posts Profit, Revenue Rise; Adjusts Guidance on Tariff Uncertainty
The healthcare-equipment company posted a rise in net profit and revenue for its fiscal second quarter but widened its adjusted earnings per share range on increased tariff uncertainty.
